Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Wyeth 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Wyeth 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth

3Q Revenues: $5.6 billion (+9%)

3Q Earnings: $1.1 billion (flat)

YTD Revenues: $16.6 billion (+10%)

YTD Earnings: $3.6 billion (+8%)

Comments: 3Q pharma revenues were up 10% to $4.7 billion, driven by a 24% boost in sales of Prevnar vaccine to $634 million and a 39% rise in ex-NA sales of Enbrel to $527 million. Top-seller Effexor posted a 4% increasse to $958 million. Earnings were impaired by a $117 million charge related to Wyeth’s ongoing restructuring.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters